A partial adenosine receptor agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Capadenoson

Item No. 28422

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile
CAS Number
544417-40-5
Synonyms
  • BAY 68-4986
Molecular Formula
C25H18ClN5O2S2
Formula Weight
520.0
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: soluble
λmax
295, 346 nm
SMILES
NC1=NC(SCC2=CSC(C3=CC=C(Cl)C=C3)=N2)=C(C#N)C(C4=CC=C(OCCO)C=C4)=C1C#N
InChi Code
InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)
InChi Key
CITWCLNVRIKQAF-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $54

    Add

    5 mg

    $238

    Add

    10 mg

    $418

    Add
    Product Description

    Capadenoson is an orally bioavailable, non-nucleoside adenosine (A) receptor partial agonist.1,2 It binds selectively to human A1 and A2B (EC50s = 0.66 and 1.1 nM, respectively) over A2A and A3 receptors (EC50s = 1,413 and 240 nM, respectively) expressed in CHO cells.1 Capadenoson (0.6 μM) decreases electrical field-stimulated norepinephrine (Item No. 16673) release from isolated perfused hearts from spontaneously hypertensive rats (SHR) but not from control rats.3 It does not affect baseline heart rate but protects against stress-induced increases in heart rate in SHR but not control rats when administered at a dose of 0.15 mg/kg for 5 days prior to stress induction. Capadenoson (0.1 mg/kg) decreases cardiac infarct size from 28.7 to 22% in a mouse model of ischemia induced by left anterior descending artery (LAD) occlusion.2 Capadenoson (7.5 mg twice per day) also increases the left ventricular ejection fraction (LVEF) in a dog model of microembolization-induced heart failure.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Baltos, J.-A., Vecchio, E.A., Harris, M.A., et al. Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism. Biochem. Pharmacol. 135, 79-89 (2017).

    2. Meibom, D., Albrecht-Küpper, B., Diedrichs, N., et al. Neladenoson bialanate hydrochloride: A prodrug of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases. ChemMedChem 12(10), 728-737 (2017).

    3. Bott-Flugel, L., Bernshausen, A., Schneider, H., et al. Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism. PLoS One 6(3), e18048 (2011).

    4. Sabbah, H.N., Gupta, R.C., Kohli, S., et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ. Heart Fail. 6(3), 563-561 (2013).